Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Bibliographic Details
Title: Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
Authors: Schjesvold, Fredrik H, Dimopoulos, Meletios-Athanasios, Delimpasi, Sosana, Robak, Pawel, Coriu, Daniel, Legiec, Wojciech, Pour, Luděk, Špička, Ivan, Masszi, Tamas, Doronin, Vadim, Minarik, Jiri, Salogub, Galina, Alekseeva, Yulia, Lazzaro, Antonio, Maisnar, Vladimir, Mikala, Gábor, Rosiñol, Laura, Liberati, Anna Marina, Symeonidis, Argiris, Moody, Victoria, Thuresson, Marcus, Byrne, Catriona, Harmenberg, Johan, Bakker, Nicolaas A, Hájek, Roman, Mateos, Maria-Victoria, Richardson, Paul G, Sonneveld, Pieter
Source: Lancet.Haematology. 9(2):e98-e110
Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100183249030.0x000001&indx=1&recIds=ETOCvdc_100183249030.0x000001
Database: British Library Document Supply Centre Inside Serials & Conference Proceedings
More Details
ISSN:23523026
Published in:Lancet.Haematology
Language:English